Patients being considered for or currently receiving checkpoint inhibitor therapies. This is the only test that can predict an individual’s likelihood of response to checkpoint inhibitors and provides useful information at the cross-roads of a patient's treatment journey.
Non-predictive diagnostic testing1
(PD-L1 IHC)
ICI response prediction before treatment2
(PD-L1 IHC)
1: Hunter, E. et al. (2021), Development and validation of blood-based predictive biomarkers for response to PD-(L)-1 checkpoint inhibitors: evidence of a universal systemic core of 3D immunogenetic profiling across multiple oncological indications. MedRxiv (2021) doi:10.1101/2021.12.21.21268094;
2: Hunter, E. et al. (2019), SITC, J. Immunotherapy Cancer 7(282) P142 & P143
Register for a meeting. One of our ESMO attendees will contact you to arrange a meeting in Paris.
To learn more about how we use your information, read our Privacy Policy.
